Cepheid (NASDAQ:CPHD)

CAPS Rating: 3 out of 5

A molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the Clinical Molecular Diagnostic, Industrial and Biothreat markets.

Recs

2
Player Avatar zzlangerhans (99.80) Submitted: 9/14/2010 2:45:57 PM : Underperform Start Price: $18.40 CPHD Score: +6.71

I'm taking advantage of an off day to go through my watchlist and see who broke through my rating thresholds. Cepheid is up steeply in September on the back of some positive press about their new TB test. That's all well and good, but it remains unclear to what extent praise from the New England Journal of Medicine will impact real world revenues. Cepheid hasn't been very impressive in that department, having yet to break even for a quarter since I've been following them. And a cash position of 46M isn't anything to write home about. I think they'll have to grow some more to fit into a one billion cap.

Featured Broker Partners


Advertisement